SCIENTIFIC PROGRAMME
Thursday, April 3, 2025
08.30 Registration Opens
​
09.30 - 09.40 Welcome Address
Michael von Bergwelt, Munich, Germany
​
09.40 - 11.10 Plenary Session 1: Tumor Immunology Inside: Novel Players
09.40 – 10.10
01.01. Neutrophils in cancer
Mikael Pittet, Geneva, Switzerland
10.10 – 10.40
01.02. Dendritic cells as orchestrators of cancer immunity
Niroshana Anandasabapathy, New York, NY, United States
10.40 – 11.10
01.03. Tregs in the cancer environment
Eliane Piaggio, Paris, France
​
11.10 - 11.40 Coffee Break
​
11.40 - 13.10 Plenary Session 2: Expect the Unexpected: Factors Influencing Immune Therapies
​
11.40 - 12.10
02.01. The influence of circadian rhythm on IO agent efficacy
Christoph Scheiermann, Geneva, Switzerland
12.10 - 12.40
02.02. Androgen influence on immunotherapy
Megan Ruhland, Portland, OR, United States
12.40 - 13.10
02.03. Local production of glucocorticoids in cancer and its therapeutic relevance
Matthew Taves, Bethesda, MD, United States
​
13.10 - 13.40 Satellite Symposium - Slot 1
​
13.40 - 15.00 Lunch & Poster Viewing
​
15.00 - 17.00 Plenary Session 3: New Targets and New Leads
​
15.00 - 15.30
03.01. Proteostatic Stress Response as Novel Opportunity for Cancer Immunotherapy
Zihai Li, Columbus, OH, United States
15.30 - 16.00
03.02. MultiOmics in pushing the frontiers in understanding the tumor microenvironment: Single cell resolution imaging
Matteo Iannacone, Milan, Italy
16.00 – 16.15 03.03. Talk from Submitted Abstracts
16.15 – 16.30 03.04. Talk from Submitted Abstracts
16.30 – 16.45 03.05. Talk from Submitted Abstracts
16.45 – 17.00 03.06. Talk from Submitted Abstracts
​
17.00 - 18.00 Plenary Session 4: Polyspecific Antibody Derivatives
​
17.00-17.30
04.01. TCR and TCR mimetics x CD3 bispecific antibodies: Expand the reach of antibodies to intracellular targets
Guillem Argilés, New York, NY, United States
17.30-18.00
04.02. Bispecific gamma-delta T-cell engagers (Gammabodies) against cancer
Hans van der Vliet, Amsterdam, The Netherlands
​
​
18.00 - 20.00 Networking Event and Poster Viewing (at the venue)
​
Friday, April 4, 2025
​
08.00 – 08.30 Satellite Symposium - Slot 2
​
08.30 – 09.30 Plenary Session 5: Pro and Con: Local vs Systemic Immunotherapy
​
08.30 – 09.00
05.01. Pro-local immunotherapies
Louisa von Baumgarten, Munich, Germany
09.00 – 09.30
05.02. Pro systemic immunotherapy
Mascha Binder, Basel, Switzerland
​
09.30 – 10.30 Plenary Session 6: Playing with the Devil: Nociception in Cancer Immunotherapy
​
09.30 – 10.00
06.01. Triggering alpha2adrenergic receptors for tumor rejection
Jingjing Zhu, Louvain, Belgium
10.00 – 10.30
06.02. Neuro-immune regulation of ILC function in anti-tumor immunity
Camilla Jandus, Geneva, Switzerland
​
10.30 – 11.00 Coffee Break
​
11.10 – 12.30 Plenary Session 7: Immune Monitoring – Omics Technology
​
11.00 – 11.30
07.01. Spatial profiling of the immune contexture in cancer: a novel translational way to attack ‘cold’ tumors
Niels Halama, Heidelberg, Germany
11.30 – 12.00
07.02. Resolving the HLA-ligandome in cancer
Juliane Walz, Tübingen, Germany
12.00 – 12.30
07.03. Liquid immunotranscriptomics-derived biomarkers for monitoring response to immunotherapy in metastatic cancer
Pedro Romero, Lausanne, Switzerland
​
12.30 - 13.00 Satellite Symposium - Slot 3 | Option 1 (30min)
12.30 - 13.30 Satellite Symposium - Slot 3 | Option 2 (60min)
​
13.00/13.30 – 14.30 Lunch & Poster Viewing
​
14.30 – 15.15 Plenary Session 8: ITOC 11 Lifetime Achievement Award
Robert D. Schreiber, St. Louis, MO, United States
​
15.15 - 16.30 Plenary Session 9: Advancing Cancer Vaccines
​
15.15 – 15.45
09.01. Neoantigen selection in tumor and lessons from flu
Paul G. Thomas, Memphis, TN, United States
15.45 – 16.15
09.02. Dysfunctional translation generates aberrant, immunogenic peptides
Wouter Scheper, Amsterdam, The Netherlands
16.15 – 16.30 09.03. Talk from Submitted Abstracts
​
16.30 - 17.00 Coffee Break
17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)
​
17.00 – 17.15 10.01. Talk from Submitted Abstracts
17.15 – 17.30 10.02. Talk from Submitted Abstracts
17.30 – 17.45 10.03. Talk from Submitted Abstracts
17.45 – 18.00 10.04. Talk from Submitted Abstracts
​
18.00 - 19.00 Poster Viewing with Presenters
​
19.15 ITOC 11 Conference Dinner
Saturday, April 5, 2025
​
08.00 – 09.00 Plenary Session 11: What Cellular Therapies Need to Work
​
08.00 – 08.30
11.01. The role of preconditioning in T cell therapy
Michal Besser, Tel Aviv, Israel
08.30 – 09.00
11.02. The role of myeloid cells in CAR T cell failure
Camille Bigenwald, Villejuif, France
​
09.00 – 10.30 Plenary Session 12 Engineering novel Cellular Immunotherapies
​
09.00 – 09.30
12.01. Novel targets of TCR therapies
Johanna Olweus, Oslo, Norway
09.30 – 10.00
12.02. Adoptive Cell Therapy, ways to enhance them
Sabine Heitzeneder, Stanford, CA, United States
10.00 – 10.30
12.03. RORing cancer with novel CAR T cells
Michael Hudecek, Würzburg, Germany
​
10.30 – 11.00 Coffee Break
​
11.00 – 12.30 Plenary Session 13: Advancing Cellular Therapies with Combinations
​
11.00 – 11.30
13.01. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors
Andreas Mackensen, Erlangen, Germany
11.30 – 12.00
13.02. Targeting TGFbeta-activated kinase-1 activation in microglia to reduce neurotoxicities of CAR T cell therapies
Robert Zeiser, Freiburg, Germany
​
12.00 – 12.15 13.03. Talk from Submitted Abstracts
12.15 – 12.30 13.04. Talk from Submitted Abstracts
12.30 – 12.45 13.05. Talk from Submitted Abstracts
​
12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks
​
13.15 – 14.15 Lunch & Farewell
​
​